Shared from parkinsonsnewstoday.com.
Microglia-driven inflammation plays an early, key role in the development of neurodegenerative diseases, including Parkinson’s disease, by contributing to the spread of abnormal protein clumps in the brain.
That’s according to study results published by a team of South Korean researchers and highlighted by Zyversa Therapeutics, which recently published data showing IC 100, its experimental therapy for Parkinson’s, prevented the activation of inflammatory pathways in microglia.
Microglia are the resident immune cells in the brain, playing a critical role in immune surveillance and inflammation. Their dysregulation and resultant neuroinflammation are recognized as contributing to the development of neurodegenerative diseases, including Parkinson’s.